A recent study published in JAMA Dermatology highlights potential risks associated with artificial intelligence (AI) dermatology mobile applications (apps), citing inconsistencies in performance, lack of regulatory approval, and insufficient transparency regarding data usage and efficacy. Researchers conducted a comprehensive analysis of 41 AI dermatology apps available in Apple and Android stores, revealing significant concerns regarding accuracy, privacy, and clinician involvement.
Despite the widespread availability of AI dermatology apps claiming to assist with skin conditions, none have gained FDA approval, raising concerns about their safety and effectiveness. The study found that a significant portion of these apps lack transparency regarding the data used for development, diagnostic accuracy, and user image storage, posing risks of biases, inappropriate recommendations, and privacy breaches. With limited clinician involvement and regulatory oversight, the researchers emphasize the need for effective regulation, validation, and standardized evaluation criteria to ensure the safety and efficacy of these apps while minimizing potential risks to patients.
